Tetratherix launches precision medicine franchise with immediate US revenue
Tetratherix (ASX: TTX) has announced the Tetratherix STEPP Precision Medicine Launch, establishing a fourth commercial franchise built on the same Tetramatrix platform polymer underpinning its existing bone regeneration, tissue spacing and tissue healing programs. The new precision medicine division launches with immediate revenue generation via an exclusive US partnership with Superpower Health Inc, delivering US$3 million annually in licensing fees for up to 10 years. Critically, the announcement confirms all existing IPO milestones remain on track, with 2 FDA approvals in bone regeneration expected mid-CY26.
The partnership centres on STEPP (Sticky Tetramatrix Enabled Precision Pharmacology), a nasal drug delivery carrier developed through over 5 years of stealth research with institutions including the Terasaki Research Institute, Ab-Initio and the Woolcock Research Institute. Unlike speculative R&D initiatives, this franchise is immediately cash-accretive through both the annual licence fee and direct polymer sales for product manufacturing.
The announcement provides revenue diversification without operational disruption. The precision medicine franchise leverages the identical polymer chemistry already validated across existing programs, meaning no diversion of research resources or capital. The company remains funded through to the start of FY28, with the Superpower agreement strengthening the balance sheet without dilution.
Ali Fathi, CTO of Tetratherix
“Our precision medicine franchise is the culmination of more than 5 years of relentless, focused R&D in drug delivery. We are now poised to transform the lives of millions across the globe, initially within the high-impact landscapes of GLP-1s and peptide therapies with Superpower. Beyond the molecules themselves, this alliance will grant us early, scaled access to real world evidence allowing us to bridge the gap between clinical potential and actual patient outcomes in record time.”
For investors, this represents platform validation beyond surgical implants. The same material science supporting bone scaffolds now generates recurring revenue in consumer precision health, demonstrating commercial versatility of the core technology.
When big ASX news breaks, our subscribers know first
What is STEPP and why does nasal drug delivery matter?
STEPP uses the Tetramatrix platform polymer in the exact same formation as the company’s bone regeneration and tissue healing franchises. When delivered as a nasal spray, the polymer forms a sticky cushion on the nasal lining that anchors compounds in place rather than allowing them to wash away. This adhesion mechanism enables controlled release of active pharmaceutical ingredients directly into the bloodstream.
The technology solves two fundamental challenges in nasal delivery. First, traditional liquid formulations drain from the nasal cavity within minutes, preventing adequate absorption. Second, delicate compounds such as GLP-1s and peptides face rapid enzymatic breakdown in the nasal environment before entering circulation. STEPP addresses both barriers through dual functionality: physical anchoring prevents drainage, whilst the polymer matrix shields fragile molecules from enzymatic degradation.
The three-step STEPP mechanism operates as follows:
- Nasal spray application delivers the compound-loaded polymer
- Sticky anchoring to nasal lining prevents wash-away effect
- Controlled compound release occurs directly into bloodstream
This matters commercially because GLP-1 therapies currently require subcutaneous injection, creating patient compliance barriers despite proven efficacy. Oral formulations face degradation in stomach acid and hepatic first-pass metabolism, reducing bioavailability. Nasal delivery bypasses the digestive system entirely whilst avoiding needles, but historically failed due to insufficient residence time in the nasal cavity and inflammatory responses to adhesive agents.
Testing since 2021 has validated STEPP against difficult-to-deliver biological payloads including mRNA, antibiotics, antibodies, proteins, peptides and growth factors. The polymer achieves adhesion without triggering inflammation, maintaining biocompatibility whilst preventing compound degradation.
For investors, this positions Tetratherix at the centre of the rapidly expanding needle-free delivery market for complex biologics. The GLP-1 segment alone represents a multi-billion-dollar addressable market, with major pharmaceutical companies actively pursuing oral and alternative delivery formats.
Superpower partnership structure and revenue mechanics
Superpower Health Inc operates an AI-driven precision health model that moves beyond reactive treatment toward proactive intervention. The company uses biomarker tracking, including blood panels and metabolic screening, to identify health issues before symptom onset and generate personalised protocols combining pharmaceutical intervention with lifestyle modification.
The Agreement establishes dual revenue streams for Tetratherix. The US$3 million annual intellectual property licence fee provides recurring revenue for up to 10 years, subject to Superpower renewals. Additionally, Superpower may purchase Tetramatrix polymer for combination with active compounds in commercial product launches, such as intranasal GLP-1 delivery formulations.
Exclusivity is limited to the United States, preserving Tetratherix’s ability to license the technology in other jurisdictions or therapeutic areas. The partnership focuses on GLP-1s, peptides, hormones and longevity compounds within Superpower’s consumer health ecosystem.
| Revenue Stream | Structure |
|---|---|
| IP Licence Fee | US$3M annually for up to 10 years |
| Polymer Sales | Direct sale of Tetramatrix polymer for product manufacturing |
| Data Value | Real-world evidence on STEPP performance across compounds |
Beyond immediate cash generation, the partnership provides access to real-world performance data across multiple compounds and patient populations. This evidence base supports future regulatory submissions and commercial expansion beyond consumer health into regulated pharmaceutical delivery.
The Agreement validates STEPP’s commercial applicability with an established US consumer health operator whilst preserving optionality for pharmaceutical partnerships, additional geographic markets, or alternative therapeutic areas.
The next major ASX story will hit our subscribers first
Platform expansion without core program disruption
The precision medicine franchise is entirely additive to existing operations. The company confirms all milestones outlined in the IPO prospectus remain on track across bone regeneration, tissue spacing and tissue healing franchises. The 2 FDA approvals in bone regeneration expected mid-CY26 remain the primary near-term value catalyst.
STEPP development occurred in parallel with core programs over more than 5 years without diverting resources, leveraging the same Tetramatrix polymer chemistry validated in surgical applications. Research partnerships with the Terasaki Research Institute, Ab-Initio and the Woolcock Research Institute supported technical development without internal resource strain.
The four Tetratherix franchises now comprise:
- Bone Regeneration (2 FDA approvals expected mid-CY26)
- Tissue Spacing
- Tissue Healing
- Precision Medicine (newly launched, immediately revenue generating)
All franchises utilise the same core Tetramatrix polymer platform, enabling interchangeable datasets and shared technical learnings across applications. This platform approach allows diversification without fragmenting research focus or duplicating infrastructure costs.
Will Knox, CEO of Tetratherix
“We are shifting the paradigm from complex implant technologies to active, high-velocity delivery systems, ensuring our technology isn’t just a part of the future of medicine but the engine that drives it. This partnership is a masterstroke in speed and strategic alignment and we couldn’t be more excited about working with Superpower as our first partner within our precision medicine franchise.”
The company remains capitalised through to the start of FY28, with the Superpower Agreement strengthening cash position without equity dilution. Revenue generation from the precision medicine franchise provides financial buffer whilst core regulatory catalysts progress toward FDA approval.
For investors, this demonstrates execution on diversification strategy whilst maintaining focus on near-term FDA catalysts. The ability to launch a revenue-generating franchise without operational disruption validates management’s platform expansion thesis.
Future development pathway
The Superpower Agreement represents the initial focus area for precision medicine franchise development, establishing revenue generation and real-world evidence collection in the US consumer health market. The company has indicated potential expansion into polymer-enabled pharmaceutical delivery applications beyond consumer health.
Future development pathways under consideration include intravascular catheter delivery of therapeutics and intra-articular joint repair applications. These represent regulated pharmaceutical applications with distinct regulatory and commercial frameworks compared to the consumer health focus of the Superpower partnership.
Management will host an investor webinar on Tuesday 17 March 2026 at 9:00AM Sydney time to discuss the announcement’s strategic significance and address shareholder questions. The webinar provides an engagement opportunity for investors seeking clarity on commercialisation timelines and expansion strategy.
The precision medicine franchise provides clear line of sight to total addressable market expansion beyond surgical implants. If successfully executed, polymer-enabled pharmaceutical delivery could position Tetratherix across multiple high-value therapeutic segments whilst maintaining operational leverage through shared platform infrastructure.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX biotech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive market-moving announcements the moment they drop, with expert coverage already done for you.